LONG-TERM (LT) THERAPY OF A FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) MAINTAINS BIOCHEMICAL RESPONSE IN PRIMARY BILIARY CIRRHOSIS (PBC)

被引：3
|
作者：
Hirschfield, G. [1 ]
Kowdley, K. [2 ]
Mason, A. [3 ]
Luketic, V. [4 ]
Gordon, S. [5 ]
Vincent, C. [6 ]
Mayo, M. [7 ]
Pares, A. [8 ]
Chapman, R. [9 ]
Lindor, K. [10 ]
Esguerra, M.
Eliot, L. [11 ]
Shapiro, D.
机构：
[1] Univ Toronto, Toronto, ON, Canada
[2] Virginia Mason Med Ctr, Seattle, WA 98101 USA
[3] Univ Alberta, Edmonton, AB, Canada
[4] Virginia Commonwealth Univ, Richmond, VA USA
[5] Henry Ford Hlth Ctr, Detroit, MI USA
[6] Hop St Luc, CHUM, Montreal, PQ H2X 1P1, Canada
[7] UT SW Med Ctr, Dallas, TX USA
[8] Hosp Clin Barcelona, Barcelona, Spain
[9] John Radcliffe Hosp, Headington, England
[10] Mayo Clin, Rochester, MN USA
[11] LKAN Clin, San Diego, CA USA
来源：
JOURNAL OF HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
10.1016/S0168-8278(12)60964-7
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
952
引用
收藏
页码：S372 / S372
页数：1
相关论文
共 50 条
  • [31] Long-term ursodeoxycholic acid therapy delays histologic progression in primary biliary cirrhosis.
    Angulo, P
    Batts, KP
    Therneau, TM
    Jorgensen, RA
    Dickson, ER
    Lindor, KD
    GASTROENTEROLOGY, 1998, 114 (04) : A1203 - A1203
  • [32] LONG-TERM OBETICHOLIC ACID (OCA) FOR PRIMARY BILIARY CHOLANGITIS (PBC) IN A CLINICAL TRIAL IMPROVED EVENT FREE SURVIVAL (DEATH, LIVER TRANSPLANT AND HEPATIC DECOMPENSATION) COMPARED TO EXTERNAL CONTROLS FROM THE GLOBAL PBC REAL-WORLD DATABASE
    Perez, Fiorella Murillo
    Adekunle, Femi
    Mayne, Tracy
    Malecha, Elizabeth
    Ness, Eric
    Van der Meer, Adriaan J.
    Lammers, Willem J.
    Trivedi, Palak J.
    Battezzati, Pier Maria
    Nevens, Frederik
    Kowdley, Kris V.
    Bruns, Tony
    Cazzagon, Nora
    Floreani, Annarosa
    Mason, Andrew L.
    Pares, Albert
    Londono, Maria
    Invernizzi, Pietro
    Carbone, Marco
    Lleo, Ana
    Mayo, Marlyn J.
    Dalekos, George N.
    Gatselis, Nikolaos K.
    Thorburn, Douglas
    Verhelst, Xavier
    Gulamhusein, Aliya
    Janssen, Harry L. A.
    Trauner, Michael
    Bowlus, Christopher
    Lindor, Keith D.
    Corpechot, Christophe
    Hirschfield, Gideon
    Hansen, Bettina E.
    GUT, 2022, 71 : A37 - A37
  • [33] Long-term obeticholic acid (OCA) for primary biliary cholangitis (PBC) in a clinical trial improved event free survival (death, liver transplant and hepatic decompensation) compared to external controls from the GLOBAL PBC real-world database
    Perez, Carla Fiorella Murillo
    Adekunle, Femi
    Mayne, Tracy
    Malecha, Elizabeth
    Ness, Erik
    Van der Meer, Adriaan
    Lammers, Willem
    Trivedi, Palak
    Battezzati, Pier Maria
    Nevens, Frederik
    Kowdley, Kris
    Bruns, Tony
    Cazzagon, Nora
    Floreani, Annarosa
    Mason, Andrew L.
    Pares, Albert
    Londono, Maria Carlota
    Invernizzi, Pietro
    Carbone, Marco
    Lleo, Ana
    Mayo, Marlyn J.
    Dalekos, George
    Gatselis, Nikolaos
    Thorburn, Douglas
    Verhelst, Xavier
    Gulamhusein, Aliya
    Janssen, Harry L. A.
    Trauner, Michael
    Bowlus, Christopher
    Lindor, Keith D.
    Corpechot, Christophe
    Hirschfield, Gideon
    Hansen, Bettina
    JOURNAL OF HEPATOLOGY, 2022, 77 : S335 - S335
  • [34] Early Biochemical Response to Ursodeoxycholic Acid and Long-Term Prognosis of Primary Biliary Cirrhosis: Results of a 14-Year Cohort Study
    Zhang, Li-Na
    Shi, Tian-Yan
    Shi, Xu-Hua
    Wang, Li
    Yang, Yun-Jiao
    Liu, Bin
    Gao, Li-Xia
    Shuai, Zong-Wen
    Kong, Fang
    Chen, Hua
    Han, Wei
    Han, Shao-Mei
    Fei, Yun-Yun
    Cui, Quan-Cai
    Wang, Qian
    Shen, Min
    Xu, Dong
    Zheng, Wen-Jie
    Li, Yong-Zhe
    Zhang, Wen
    Zhang, Xuan
    Zhang, Feng-Chun
    HEPATOLOGY, 2013, 58 (01) : 264 - 272
  • [35] Biochemical response after one year is associated with excellent long-term survival in patients with primary biliary cirrhosis treated with ursodeoxycholic acid
    Pares, A
    Caballeria, L
    Rodes, J
    JOURNAL OF HEPATOLOGY, 2005, 42 : 234 - 234
  • [36] Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis
    van Hoogstraten, HJE
    Hansen, BE
    van Buuren, HR
    ten Kate, FJW
    van Berge-Henegouwen, GP
    Schalm, SW
    JOURNAL OF HEPATOLOGY, 1999, 31 (02) : 256 - 262
  • [37] Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years
    Chan, CW
    Gunsar, F
    Feudjo, M
    Rigamonti, C
    Vlachogiannakos, J
    Carpenter, JR
    Burroughs, AK
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (03) : 217 - 226
  • [38] LONG-TERM EFFECT OF URSODEOXYCHOLIC ACID (UDCA) ON HEPATIC-FUNCTION AND PORTAL-HYPERTENSION IN PRIMARY BILIARY-CIRRHOSIS (PBC)
    HUET, PM
    HUET, J
    HOTTE, S
    HEPATOLOGY, 1994, 20 (04) : A202 - A202
  • [39] Primary Biliary Cholangitis (PBC)-Autoimmune Hepatitis (AIH) Variant Syndrome: Clinical Features, Response to Therapy and Long-Term Outcome
    Graf, Markus
    Lange, Christian M.
    Langer, Mona M.
    Schattenberg, Joern M.
    Seessle, Jessica
    Dietz, Julia
    Vermehren, Annika
    Michael, Florian A.
    Mondorf, Antonia
    Zeuzem, Stefan
    Pathil, Anita
    Graf, Christiana
    Kaplan, David E.
    Kato, Hideaki
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (22)
  • [40] EFFECT OF LONG-TERM TREATMENT WITH URSODIOL ON CLINICAL AND BIOCHEMICAL FEATURES AND BILIARY BILE-ACID METABOLISM IN PATIENTS WITH PRIMARY BILIARY-CIRRHOSIS
    BATTA, AK
    SALEN, G
    MIRCHANDANI, R
    TINT, GS
    SHEFER, S
    BATTA, M
    ABROON, J
    OBRIEN, CB
    SENIOR, JR
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1993, 88 (05): : 691 - 700
12345